PM Workshops; All Day Training Course; AM Early Career Session - PT (Pacific Time, GMT-08:00)
PM Workshops; All Day Training Course; AM Early Career Session - PT (Pacific Time, GMT-08:00)
Optional Pre-Conference Training Course (9:00am-5:00pm); Pre-Conference Workshops (1:00pm-5:00pm); Early Career Session (9:00am-12:00pm)
8:30am - 9:00am30 mins
Training Course: Introduction to Antibody Engineering
Training Course Registration
9:00am - 5:00pm480 mins
Training Course: Introduction to Antibody Engineering
Introduction to Antibody Engineering
- David Bramhill, PhD - Consultant, Bramhill Biological Consulting, LLC
9:00am - 9:10am10 mins
Early Career Scientist Session
Session Co-Chair Welcome and Opening Remarks
- Karen Silence, PhD - Head Preclinical Product Development, Argenx
- Robert Chen, PhD - Antibody Engineer, Chai Discovery
9:10am - 9:40am30 mins
Early Career Scientist Session
Fun Icebreaker with Antibody Quiz Game
9:40am - 10:00am20 mins
Early Career Scientist Session
Early Career Scientist Presentation #1
10:00am - 10:20am20 mins
Early Career Scientist Session
Early Career Scientist Presentation #2
10:20am - 10:40am20 mins
Early Career Scientist Session
Early Career Scientist Presentation #3
10:40am - 11:00am20 mins
Early Career Scientist Session
Early Career Scientist Presentation #4
11:00am - 11:45am45 mins
Early Career Scientist Session
Career Path/Experiences Panel Discussion
- Jonathan Sockolosky, PhD - Co-founder and CEO, Macaw Therapeutics
- Krista Kinneer - Director, Oncology Translational Medicine, AstraZeneca
- Clarice Mengwen Zhang - Postdoctoral Fellow, Genentech
11:45am - 12:00pm15 mins
Early Career Scientist Session
Closing Remarks
1:00pm - 1:15pm15 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
- Bassil Dahiyat, PhD - President and CEO, Xencor
- Stephanie Casey Parks, PhD - Senior Principal Scientist, Amgen
1:00pm - 1:15pm15 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Co-Chairs’ Remarks- Engineering Considerations for Candidate Selection and Developability
- Peter Tessier, PhD - Albert M. Mattocks Professor, Departments of Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering, University of Michigan
- Mark Julian, PhD - Principal Scientist, Antibody Discovery & Engineering, Atlas Venture NewCo
1:15pm - 1:45pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Key Design Decisions for Bispecific Molecules
- David Shen, PhD - CEO, Propeller Bio
1:15pm - 1:45pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Developability-Guided Generative Biology for Therapeutic Protein Engineering
- Marissa Mock, PhD - Executive Director of Protein Therapeutics, Amgen
1:45pm - 2:15pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers
- Nichole Escalante, PhD - Senior Scientist and Group Lead, Zymeworks
1:45pm - 2:15pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
A Combined Computational and Experimental Cascade for Variable Domain Assessment and Optimization Towards Developable Multispecific Antibodies
- Andreas Evers - Scientific Director in Antibody Discovery & Protein Engineering, Global Research & Development, Discovery Technologies, Merck Healthcare
2:15pm - 2:45pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Risankizumab: It’s Not Magic, It’s Pure Logic
- Sanjaya Singh, PhD - Founder and Chief Scientific Officer, Third Arc Bio
2:15pm - 2:45pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics
- Steven Jacobs, PhD - Senior Director of Biophysics & Molecular Attributes within Therapeutics Discovery, Johnson & Johnson Innovative Medicine
2:45pm - 3:15pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Networking Refreshment Break
2:45pm - 3:15pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Networking Refreshment Break
3:15pm - 3:45pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Ozekibart: A Tetravalent Antibody Precisely Engineered for Optimal DR5 Agonism and Safety
- Katelyn Willis - Group Leader - Cell Biology, InhibRx
3:15pm - 3:45pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Hybrid Molecular Modeling and Machine Learning for Screening Viscosity-Reducing Excipients in Antibody Formulations
- Pin-Kuang Lai - Assistant Professor, Stevens Institute of Technology
3:45pm - 4:15pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics
- Saileta Prabhu, PhD - Clinical Pharmacologist, Regeneron
3:45pm - 4:15pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Antibody Polyspecificity Profiling
- Arvind Sivasubramanian, PhD - Senior Director, Computational Biology & Platform, Adimab
4:15pm - 4:45pm30 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Late Breaking Presentation
4:15pm - 4:45pm30 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Beyond Sequence Prediction: Integrating AI-Driven In Silico Analysis with Human Immune Assays for Antibody Engineering
- Vibha Jawa - Chief Scientific Officer, EpiVax, Inc
4:45pm - 5:00pm15 mins
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right
Concluding Remarks
4:45pm - 5:00pm15 mins
Workshop 2: Engineering Considerations for Candidate Selection and Developability
Concluding Remarks
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。